These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34387173)

  • 21. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience.
    Montefusco A; De Filippo O; Gili S; Mancone M; Calcagno S; Cirillo P; Esposito G; Poli A; Ferrara E; Smolka G; Wanha W; Palmieri C; Pastormerlo LE; Baumbach A; Sganzerla P; Tamburino C; Bruno F; Secco GG; Nicolino A; Yew KL; di Palma G; Wojakowski W; Sardella G; Rinaldi M; Cortese B; D'Ascenzo F
    Coron Artery Dis; 2020 Jan; 31(1):27-34. PubMed ID: 31658146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
    Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
    Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial.
    Dani S; Costa RA; Joshi H; Shah J; Pandya R; Virmani R; Sheiban I; Bhatt S; Abizaid A
    EuroIntervention; 2013 Aug; 9(4):493-500. PubMed ID: 23965355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Upfront Two-Stent Strategy for True Coronary Bifurcation Lesions with A Large Side Branch in Acute Coronary Syndrome: A Two-Year Follow-Up Study.
    Yurtdaş M; Asoğlu R; Özdemir M; Asoğlu E
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32121323
    [No Abstract]   [Full Text] [Related]  

  • 29. Three-Year Outcomes of Biodegradable Polymer-Coated Ultra-Thin (60 µm) Sirolimus-Eluting Stents in Real-World Clinical Practice.
    Chandwani P; Meel B; Singhal R; Jangid K; Ahmed R; Yadav M; Gupta AK; Chopra R
    Ann Acad Med Singap; 2019 May; 48(5):150-155. PubMed ID: 31210252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study.
    Jain RK; Chakravarthi P; Shetty R; Ramchandra P; Polavarapu RS; Wander GS; Mohan B; Banker DN; Dharmadhikari A; Bansal SS; Jain N; Solanki D; Dhakaan J; Sharma VP; Mohanan PP; Ashokan PK; Manjunath BV; Hiregoudar N; Patil C; Balakrishnan N
    Indian Heart J; 2016; 68(5):599-603. PubMed ID: 27773396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of older patients affected by coronary artery disease: results from a single-center allcomers registry.
    Buja P; Lanzellotti D; Isabella G; Napodano M; Panfili M; Favaretto E; Iliceto S; Tarantini G
    Heart Vessels; 2012 Nov; 27(6):553-8. PubMed ID: 21989862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical performance of a dedicated self-apposing stent for the treatment of left main stem disease. Results of the left Main AngioplasTy wIth a Self-apposing StEnt - the MATISSE study.
    Cortese B; Montefusco A; D'Ascenzo F; La Manna A; Andò G; Bisceglia T; Secco GG; Meyer-Gessner M; Wańha W; Sganzerla P; Napodano M; Di Palma G; Latini RA; Tamburino C; Orrego PS; Baumbach A
    Cardiovasc Revasc Med; 2018; 19(7 Pt B):831-836. PubMed ID: 29661597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions.
    Burzotta F; Summaria F; Latib A; De Vita M; Fantoni C; Benedetto S; Turturo M; Larosa C; Manzoli A; Trani C
    Catheter Cardiovasc Interv; 2016 Jan; 87(1):15-22. PubMed ID: 25914397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome of patients with de novo coronary bifurcation lesions treated with the Tryton Side Branch Stent. The SAFE-TRY prospective multicenter single arm study.
    Tarantini G; La Vecchia L; Galli M; Favero L; D'Amico G; Buja P; Russo F; Cabianca E; Napodano M; Musumeci G; Franceschini E; Grassi G; Pavei A; Bonmassari R; Cernetti C; Spedicato L; Caprioglio F; Reimers B; Isabella G
    Int J Cardiol; 2013 Oct; 168(6):5323-8. PubMed ID: 24007969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
    Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
    Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
    Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study.
    Saito S; Ando K; Ito Y; Tobaru T; Yajima J; Kimura T; Kadota K
    Cardiovasc Interv Ther; 2019 Jan; 34(1):25-33. PubMed ID: 29349686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.